Should treatment of low-level rifampicin mono-resistant tuberculosis be different?

Should treatment of low-level rifampicin mono-resistant tuberculosis be different?

Background: Rifampicin resistant tuberculosis (RR-TB) was frequently detected in Suriname after the introduction of Xpert MTB/RIF in 2012. Subsequent phenotypic drug-susceptibility testing (DST) was not conclusive at that moment, while RR-TB patients treated with first-line tuberculostatics had good...

Full description

Bibliographic Details
Main Authors: F.A. Gopie, E. Commiesie, S. Baldi, M. Kamst, D. Kaur, W.C.M. de Lange, P.S. Pinas, D. Stijnberg, M. Wongsokarijo, C.W.R. Zijlmans, R. de Zwaan, D. van Soolingen, S.G.S. Vreden, G. de Vries
Format: Article
Language:English
Published: Elsevier 2021-05-01
Series:Journal of Clinical Tuberculosis and Other Mycobacterial Diseases
Subjects:
Drug resistance
Treatment Outcome
Xpert MTB/RIF
Drug-susceptibility testing
Tuberculosis
Online Access:http://www.sciencedirect.com/science/article/pii/S2405579421000115

Internet

http://www.sciencedirect.com/science/article/pii/S2405579421000115

Similar Items